Maitri Enterprises Ltd
Incorporated in 1991, Maitri Enterprises Ltd is engaged in the business of Pharmaceutical products
- Market Cap ₹ 16.2 Cr.
- Current Price ₹ 36.8
- High / Low ₹ 41.5 / 20.1
- Stock P/E
- Book Value ₹ 10.3
- Dividend Yield 0.00 %
- ROCE 2.43 %
- ROE -9.48 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.58 times its book value
- Company has low interest coverage ratio.
- Company has high debtors of 168 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
4.55 | 19.92 | 13.32 | 19.01 | |
4.47 | 19.23 | 12.82 | 18.76 | |
Operating Profit | 0.08 | 0.69 | 0.50 | 0.25 |
OPM % | 1.76% | 3.46% | 3.75% | 1.32% |
0.09 | 0.06 | 0.11 | 0.13 | |
Interest | 0.02 | 0.32 | 0.37 | 0.73 |
Depreciation | 0.05 | 0.09 | 0.07 | 0.06 |
Profit before tax | 0.10 | 0.34 | 0.17 | -0.41 |
Tax % | 40.00% | 32.35% | 94.12% | 9.76% |
0.07 | 0.23 | 0.00 | -0.45 | |
EPS in Rs | 0.37 | 0.52 | 0.00 | -1.02 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 61% |
TTM: | 43% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | % |
3 Years: | 62% |
1 Year: | 46% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Equity Capital | 4.40 | 4.40 | 4.40 | |
Reserves | 0.57 | 0.57 | 0.12 | |
5.72 | 6.34 | 10.55 | ||
6.85 | 7.09 | 6.60 | ||
Total Liabilities | 17.54 | 18.40 | 21.67 | |
0.28 | 0.24 | 0.24 | ||
CWIP | 0.00 | 0.00 | 0.00 | |
Investments | 0.27 | 0.27 | 3.92 | |
16.99 | 17.89 | 17.51 | ||
Total Assets | 17.54 | 18.40 | 21.67 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-0.39 | 0.02 | 0.06 | ||
-3.27 | -0.24 | -3.45 | ||
3.69 | 0.24 | 3.49 | ||
Net Cash Flow | 0.03 | 0.02 | 0.10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 163.81 | 204.70 | 168.00 | |
Inventory Days | 210.48 | 261.85 | 149.78 | |
Days Payable | 186.79 | 206.97 | 122.59 | |
Cash Conversion Cycle | 187.50 | 259.58 | 195.19 | |
Working Capital Days | 157.76 | 247.17 | 176.45 | |
ROCE % | 4.91% | 2.43% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended on June 30, 2024.
- Closure of Trading Window 26 Jun
- Clarifications On Delayed Submission Of Financial Results For The Quarter And Year Ended On March 31, 2024 For Late Submission With Respect To Outcome Of Board Meeting. 8 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Newspaper Advertisement for Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended on March 31, 2024.
- Non-Applicability Of Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (LODR) Regulations, 2015. 30 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
a) Trading of Pharmaceutical & Medical Goods
b) Manufacturing of metal furniture
c) Trading of building materials